1 Market Overview
    1.1 Peptide Drug CDMO Definition
    1.2 Global Peptide Drug CDMO Market Size and Forecast
    1.3 China Peptide Drug CDMO Market Size and Forecast
    1.4 Share of China Peptide Drug CDMO Market with Respect to the Global Market
    1.5 Peptide Drug CDMO Market Size: China VS Global Growth Rate, 2019-2030
    1.6 Peptide Drug CDMO Market Dynamics
        1.6.1 Peptide Drug CDMO Market Drivers
        1.6.2 Peptide Drug CDMO Market Restraints
        1.6.3 Peptide Drug CDMO Industry Trends
        1.6.4 Peptide Drug CDMO Industry Policy
2 Global Leading Players and Market Share
    2.1 By Revenue of Peptide Drug CDMO, Global Market Share by Company, 2019-2024
    2.2 Global Peptide Drug CDMO Participants, Market Position (Tier 1, Tier 2, and Tier 3)
    2.3 Global Peptide Drug CDMO Concentration Ratio
    2.4 Global Peptide Drug CDMO Mergers & Acquisitions, Expansion Plans
    2.5 Global Peptide Drug CDMO Major Companies Product Type
    2.6 Head Office and Area Served of Key Players
3 China Leading Players, Market Share and Ranking
    3.1 By Revenue of Peptide Drug CDMO, China Market Share by Company, 2019-2024
    3.2 China Peptide Drug CDMO Peptide Drug CDMO Participants, Market Position (Tier 1, Tier 2, and Tier 3)
4 Industry Chain Analysis
    4.1 Peptide Drug CDMO Industry Chain
    4.2 Peptide Drug CDMO Upstream Analysis
        4.2.1 Peptide Drug CDMO Core Raw Materials
        4.2.2 Main Manufacturers of Peptide Drug CDMO Core Raw Materials
    4.3 Midstream Analysis
    4.4 Downstream Analysis
    4.5 Peptide Drug CDMO Production Mode
    4.6 Peptide Drug CDMO Procurement Model
    4.7 Peptide Drug CDMO Industry Sales Model and Sales Channels
        4.7.1 Peptide Drug CDMO Sales Model
        4.7.2 Peptide Drug CDMO Typical Distributors
5 Sights by Type
    5.1 Peptide Drug CDMO Classification
        5.1.1 APIs and Intermediates
        5.1.2 FDF
    5.2 by Type, Global Peptide Drug CDMO Consumption Value & CAGR, 2019 VS 2023 VS 2030
    5.3 by Type, Global Peptide Drug CDMO Consumption Value, 2019-2030
6 Sights by Application
    6.1 Peptide Drug CDMO Segment by Application
        6.1.1 Antineoplastic Drugs
        6.1.2 Geno-Urinary System and Sex Hormones
        6.1.3 Cardiovascular System Drugs
        6.1.4 Anti-Infective Drugs
    6.2 by Application, Global Peptide Drug CDMO Consumption Value & CAGR, 2019 VS 2023 VS 2030
    6.3 by Application, Global Peptide Drug CDMO Consumption Value, 2019-2030
7 Sales Sights by Region
    7.1 By Region, Global Peptide Drug CDMO Consumption Value, 2019 VS 2023 VS 2030
    7.2 By Region, Global Peptide Drug CDMO Consumption Value, 2019-2030
    7.3 North America
        7.3.1 North America Peptide Drug CDMO Market Size & Forecasts, 2019-2030
        7.3.2 By Country, North America Peptide Drug CDMO Market Size Market Share
    7.4 Europe
        7.4.1 Europe Peptide Drug CDMO Market Size & Forecasts, 2019-2030
        7.4.2 By Country, Europe Peptide Drug CDMO Market Size Market Share
    7.5 Asia Pacific
        7.5.1 Asia Pacific Peptide Drug CDMO Market Size & Forecasts, 2019-2030
        7.5.2 By Country/Region, Asia Pacific Peptide Drug CDMO Market Size Market Share
    7.6 South America
        7.6.1 South AmericaPeptide Drug CDMO Market Size & Forecasts, 2019-2030
        7.6.2 By Country, South America Peptide Drug CDMO Market Size Market Share
    7.7 Middle East & Africa
8 Sales Sights by Country Level
    8.1 By Country, Global Peptide Drug CDMO Market Size & CAGR, 2019 VS 2023 VS 2030
    8.2 By Country, Global Peptide Drug CDMO Consumption Value, 2019-2030
    8.3 U.S.
        8.3.1 U.S.Peptide Drug CDMO Market Size, 2019-2030
        8.3.2 by Type, U.S. Peptide Drug CDMO Consumption Value Market Share, 2023 VS 2030
        8.3.3 by Application, U.S. Peptide Drug CDMO Consumption Value Market Share, 2023 VS 2030
    8.4 Europe
        8.4.1 Europe Peptide Drug CDMO Market Size, 2019-2030
        8.4.2 by Type, Europe Peptide Drug CDMO Consumption Value Market Share, 2023 VS 2030
        8.4.3 by Application, Europe Peptide Drug CDMO Consumption Value Market Share, 2023 VS 2030
    8.5 China
        8.5.1 China Peptide Drug CDMO Market Size, 2019-2030
        8.5.2 by Type, China Peptide Drug CDMO Consumption Value Market Share, 2023 VS 2030
        8.5.3 by Application, China Peptide Drug CDMO Consumption Value Market Share, 2023 VS 2030
    8.6 Japan
        8.6.1 Japan Peptide Drug CDMO Market Size, 2019-2030
        8.6.2 by Type, Japan Peptide Drug CDMO Consumption Value Market Share, 2023 VS 2030
        8.6.3 by Application, Japan Peptide Drug CDMO Consumption Value Market Share, 2023 VS 2030
    8.7 South Korea
        8.7.1 South Korea Peptide Drug CDMO Market Size, 2019-2030
        8.7.2 by Type, South Korea Peptide Drug CDMO Consumption Value Market Share, 2023 VS 2030
        8.7.3 by Application, South Korea Peptide Drug CDMO Consumption Value Market Share, 2023 VS 2030
    8.8 Southeast Asia
        8.8.1 Southeast Asia Peptide Drug CDMO Market Size, 2019-2030
        8.8.2 by Type, Southeast Asia Peptide Drug CDMO Consumption Value Market Share, 2023 VS 2030
        8.8.3 by Application, Southeast Asia Peptide Drug CDMO Consumption Value Market Share, 2023 VS 2030
    8.9 India
        8.9.1 India Peptide Drug CDMO Market Size, 2019-2030
        8.9.2 by Type, India Peptide Drug CDMO Consumption Value Market Share, 2023 VS 2030
        8.9.3 by Application, India Peptide Drug CDMO Consumption Value Market Share, 2023 VS 2030
    8.10 Middle East & Africa
        8.10.1 Middle East & Africa Peptide Drug CDMO Market Size, 2019-2030
        8.10.2 by Type, Middle East & Africa Peptide Drug CDMO Consumption Value Market Share, 2023 VS 2030
        8.10.3 by Application, Middle East & Africa Peptide Drug CDMO Consumption Value Market Share, 2023 VS 2030
9 Company Profile
    9.1 Bachem
        9.1.1 Bachem Company Information, Head Office, Market Area, and Industry Position
        9.1.2 Bachem Company Profile and Main Business
        9.1.3 Bachem Peptide Drug CDMO Models, Specifications, and Application
        9.1.4 Bachem Peptide Drug CDMO Revenue and Gross Margin, 2019-2024
        9.1.5 Bachem Recent Developments
    9.2 PolyPeptide
        9.2.1 PolyPeptide Company Information, Head Office, Market Area, and Industry Position
        9.2.2 PolyPeptide Company Profile and Main Business
        9.2.3 PolyPeptide Peptide Drug CDMO Models, Specifications, and Application
        9.2.4 PolyPeptide Peptide Drug CDMO Revenue and Gross Margin, 2019-2024
        9.2.5 PolyPeptide Recent Developments
    9.3 CordenPharma
        9.3.1 CordenPharma Company Information, Head Office, Market Area, and Industry Position
        9.3.2 CordenPharma Company Profile and Main Business
        9.3.3 CordenPharma Peptide Drug CDMO Models, Specifications, and Application
        9.3.4 CordenPharma Peptide Drug CDMO Revenue and Gross Margin, 2019-2024
        9.3.5 CordenPharma Recent Developments
    9.4 AmbioPharm
        9.4.1 AmbioPharm Company Information, Head Office, Market Area, and Industry Position
        9.4.2 AmbioPharm Company Profile and Main Business
        9.4.3 AmbioPharm Peptide Drug CDMO Models, Specifications, and Application
        9.4.4 AmbioPharm Peptide Drug CDMO Revenue and Gross Margin, 2019-2024
        9.4.5 AmbioPharm Recent Developments
    9.5 USV Peptides
        9.5.1 USV Peptides Company Information, Head Office, Market Area, and Industry Position
        9.5.2 USV Peptides Company Profile and Main Business
        9.5.3 USV Peptides Peptide Drug CDMO Models, Specifications, and Application
        9.5.4 USV Peptides Peptide Drug CDMO Revenue and Gross Margin, 2019-2024
        9.5.5 USV Peptides Recent Developments
    9.6 Thermofischer
        9.6.1 Thermofischer Company Information, Head Office, Market Area, and Industry Position
        9.6.2 Thermofischer Company Profile and Main Business
        9.6.3 Thermofischer Peptide Drug CDMO Models, Specifications, and Application
        9.6.4 Thermofischer Peptide Drug CDMO Revenue and Gross Margin, 2019-2024
        9.6.5 Thermofischer Recent Developments
    9.7 Bio Basic
        9.7.1 Bio Basic Company Information, Head Office, Market Area, and Industry Position
        9.7.2 Bio Basic Company Profile and Main Business
        9.7.3 Bio Basic Peptide Drug CDMO Models, Specifications, and Application
        9.7.4 Bio Basic Peptide Drug CDMO Revenue and Gross Margin, 2019-2024
        9.7.5 Bio Basic Recent Developments
    9.8 JPT
        9.8.1 JPT Company Information, Head Office, Market Area, and Industry Position
        9.8.2 JPT Company Profile and Main Business
        9.8.3 JPT Peptide Drug CDMO Models, Specifications, and Application
        9.8.4 JPT Peptide Drug CDMO Revenue and Gross Margin, 2019-2024
        9.8.5 JPT Recent Developments
    9.9 Genscript
        9.9.1 Genscript Company Information, Head Office, Market Area, and Industry Position
        9.9.2 Genscript Company Profile and Main Business
        9.9.3 Genscript Peptide Drug CDMO Models, Specifications, and Application
        9.9.4 Genscript Peptide Drug CDMO Revenue and Gross Margin, 2019-2024
        9.9.5 Genscript Recent Developments
    9.10 Xinbang Pharma
        9.10.1 Xinbang Pharma Company Information, Head Office, Market Area, and Industry Position
        9.10.2 Xinbang Pharma Company Profile and Main Business
        9.10.3 Xinbang Pharma Peptide Drug CDMO Models, Specifications, and Application
        9.10.4 Xinbang Pharma Peptide Drug CDMO Revenue and Gross Margin, 2019-2024
        9.10.5 Xinbang Pharma Recent Developments
    9.11 ScinoPharm
        9.11.1 ScinoPharm Company Information, Head Office, Market Area, and Industry Position
        9.11.2 ScinoPharm Company Profile and Main Business
        9.11.3 ScinoPharm Peptide Drug CDMO Models, Specifications, and Application
        9.11.4 ScinoPharm Peptide Drug CDMO Revenue and Gross Margin, 2019-2024
        9.11.5 ScinoPharm Recent Developments
    9.12 SN Biopharm
        9.12.1 SN Biopharm Company Information, Head Office, Market Area, and Industry Position
        9.12.2 SN Biopharm Company Profile and Main Business
        9.12.3 SN Biopharm Peptide Drug CDMO Models, Specifications, and Application
        9.12.4 SN Biopharm Peptide Drug CDMO Revenue and Gross Margin, 2019-2024
        9.12.5 SN Biopharm Recent Developments
    9.13 CBL
        9.13.1 CBL Company Information, Head Office, Market Area, and Industry Position
        9.13.2 CBL Company Profile and Main Business
        9.13.3 CBL Peptide Drug CDMO Models, Specifications, and Application
        9.13.4 CBL Peptide Drug CDMO Revenue and Gross Margin, 2019-2024
        9.13.5 CBL Recent Developments
    9.14 Piramal Pharma
        9.14.1 Piramal Pharma Company Information, Head Office, Market Area, and Industry Position
        9.14.2 Piramal Pharma Company Profile and Main Business
        9.14.3 Piramal Pharma Peptide Drug CDMO Models, Specifications, and Application
        9.14.4 Piramal Pharma Peptide Drug CDMO Revenue and Gross Margin, 2019-2024
        9.14.5 Piramal Pharma Recent Developments
    9.15 CPC Scientific
        9.15.1 CPC Scientific Company Information, Head Office, Market Area, and Industry Position
        9.15.2 CPC Scientific Company Profile and Main Business
        9.15.3 CPC Scientific Peptide Drug CDMO Models, Specifications, and Application
        9.15.4 CPC Scientific Peptide Drug CDMO Revenue and Gross Margin, 2019-2024
        9.15.5 CPC Scientific Recent Developments
10 Conclusion
11 Appendix
    11.1 Research Methodology
    11.2 Data Source
        11.2.1 Secondary Sources
        11.2.2 Primary Sources
    11.3 Market Estimation Model
    11.4 Disclaimer